Press Release | November 20, 2023
Cantai Therapeutics is Co-Founded by Agent Capital and 82VS to Advance Next-Generation Bispecific Antibodies for Autoimmune Diseases
Read More
News | October 25, 2023
A new era in medicine: unraveling the evolution and future of gene therapy
Read More
News | October 23, 2023
Skyhawk Therapeutics Receives HREC Approval for a Phase 1 Study of its SKY-0515 RNA-Targeting Small Molecule for Huntington’s Disease
Read More
News | October 19, 2023
Flare Therapeutics Announces First Patients Dosed in First-in-Human Phase 1 Clinical Study of FX-909 in Advanced Solid Malignancies, Including Urothelial Cancer
Read More
